

## MD Anderson Ovarian SPORE publications – 2019

1. Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. **Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.** *Cancer*. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5. PMID: 30835824
2. Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ. **Advancing Drug Development in Gynecologic Malignancies.** *Clin Cancer Res*. 2019 Aug 15;25(16):4874-4880. doi: 10.1158/1078-0432.CCR-19-0619. Epub 2019 May 24. PMID: 31126961
3. Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, Lu KH. **Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.** *Gynecol Oncol*. 2019 Feb;152(2):328-333. doi: 10.1016/j.ygyno.2018.12.001. Epub 2018 Dec 8. PMID: 30528888
4. Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN. **Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.** *Ann Oncol*. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104. PMID: 30887020 Review.
5. Chelariu-Raicu A, Coleman RL, Sood AK. **Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?** *Oncology (Williston Park)*. 2019 Jul 16;33(7):629378. PMID: 31365748 Review.
6. Chen X, Mangala LS, Mooberry L, Bayraktar E, Dasari SK, Ma S, Ivan C, Court KA, Rodriguez-Aguayo C, Bayraktar R, Raut S, Sabnis N, Kong X, Yang X, Lopez-Berestein G, Lacko AG, Sood AK. **Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.** *Oncogene*. 2019 Aug;38(33):6095-6108. doi: 10.1038/s41388-019-0862-y. Epub 2019 Jul 9. PMID: 31289363
7. Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA. **Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.** *N Engl J Med*. 2019 Dec 19;381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28. PMID: 31562800 Clinical Trial.
8. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. **Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.** *N Engl J Med*. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. PMID: 31722153 Clinical Trial.
9. Cuneo MG, Szeto A, Schrepf A, Kinner EM, Schachner BI, Ahmed R, Thaker PH, Goodheart M, Bender D, Cole SW, McCabe PM, Sood AK, Lutgendorf SK, Mendez AJ. **Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.** *Psychoneuroendocrinology*. 2019 Aug;106:244-251. doi: 10.1016/j.psyneuen.2019.04.007. Epub 2019 Apr 6. PMID: 31005045
10. Dottino JA, He W, Sun CC, Zhao H, Fu S, Lu KH, Meyer LA. **Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.** *Gynecol Oncol*. 2019 Aug;154(2):405-410. doi: 10.1016/j.ygyno.2019.06.003. Epub 2019 Jun 14. PMID: 31208738 Clinical Trial.
11. Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ. **U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A**

- Cost-Effectiveness Analysis.** *Obstet Gynecol.* 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171. PMID: 30870286
12. Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrisnan K, Zhou X, Leonard EJ, Schilder RJ. **Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.** *JAMA Oncol.* 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10. PMID: 30347019 Clinical Trial.
  13. Falchook G, Coleman RL, Schilder RJ. **Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.** *JAMA Oncol.* 2019 Jun 1;5(6):910-911. doi: 10.1001/jamaoncol.2019.0562. PMID: 31021370 No abstract available.
  14. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. **Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.** *Cancer Cell.* 2019 Jun 10;35(6):851-867.e7. doi: 10.1016/j.ccell.2019.05.001. PMID: 31185210
  15. Gaillard SL, Coleman RL. **Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?** *Ann Oncol.* 2019 Jul 1;30(7):1025-1028. doi: 10.1093/annonc/mdz166. PMID: 31111866 No abstract available.
  16. Gallagher JR, Heap KJ, Carroll S, Travers K, Harrow B, Westin SN. **Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.** *Future Oncol.* 2019 Dec;15(36):4197-4206. doi: 10.2217/fon-2019-0471. Epub 2019 Nov 11. PMID: 31707856
  17. Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL. **Correction: Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer.** *J Exp Med.* 2019 Oct 7;216(10):2448. doi: 10.1084/jem.2018076508222019c. PMID: 31591188 No abstract available.
  18. Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, Wei X, Liu D, Sun C, Chen G, Hu J, Meng L, Zhou J, Sawada K, Fruscio R, Grunt TW, Wischhusen J, Vargas-Hernández VM, Pothuri B, Coleman RL. **Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer.** *J Exp Med.* 2019 Mar 4;216(3):688-703. doi: 10.1084/jem.20180765. Epub 2019 Feb 1. PMID: 30710055
  19. Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirolo KF, Flores ER, Chang EH. **Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.** *Cancer.* 2019 Jul 15;125(14):2409-2422. doi: 10.1002/cncr.32053. Epub 2019 Apr 23. PMID: 31012964
  20. Guo J, Yang WL, Pak D, Celestino J, Lu K H, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC Jr. **Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.** *Cancers (Basel).* 2019 Apr 28;11(5):596. doi: 10.3390/cancers11050596. PMID: 31035430
  21. Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. **Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.** *Clin Cancer Res.* 2019 May 15;25(10):3194. doi: 10.1158/1078-0432.CCR-19-1132. PMID: 31092618 No abstract available.
  22. Hinchcliff E, Jazaeri AA. **Sunset, or dawn of a new age for ovarian cancer vaccine therapy?** *Gynecol Oncol.* 2019 Dec;155(3):387-388. doi: 10.1016/j.ygyno.2019.11.011. PMID: 31812214 No abstract available.
  23. Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri A. **Lymphocyte-specific kinase expression is a prognostic indicator in ovarian**

- cancer and correlates with a prominent B cell transcriptional signature.** *Cancer Immunol Immunother.* 2019 Sep;68(9):1515-1526. doi: 10.1007/s00262-019-02385-x. Epub 2019 Sep 12. PMID: 31515669
24. Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL. **Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.** *Int J Gynecol Cancer.* 2019 May 22;ijgc-2019-000499. doi: 10.1136/ijgc-2019-000499. Online ahead of print. PMID: 31118216
25. Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA. **Disparities in gynecologic cancer genetics evaluation.** *Gynecol Oncol.* 2019 Apr;153(1):184-191. doi: 10.1016/j.ygyno.2019.01.024. Epub 2019 Jan 31. PMID: 30711300 Review.
26. Hisamatsu T, McGuire M, Wu SY, Rupaimoole R, Pradeep S, Bayraktar E, Noh K, Hu W, Hansen JM, Lyons Y, Gharpure KM, Nagaraja AS, Mangala LS, Mitamura T, Rodriguez-Aguayo C, Eun YG, Rose J, Bartholomeusz G, Ivan C, Lee JS, Matsuo K, Frumovitz M, Wong KK, Lopez-Berestein G, Sood AK. **PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.** *Mol Cancer Ther.* 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10. PMID: 30305341
27. Iavarone C, Zervantonakis IK, Selfors LM, Palakurthi S, Liu JF, Drapkin R, Matulonis UA, Hallberg D, Velculescu VE, Levenson JD, Sampath D, Mills GB, Brugge JS. **Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.** *Mol Cancer Ther.* 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24. PMID: 30679390
28. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Ceirbhail RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. **Olaparib and  $\alpha$ -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.** *Lancet Oncol.* 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14. PMID: 30880072 Clinical Trial.
29. Kurnit KC, Sinno AK, Fellman BM, Varghese A, Stone R, Sood AK, Gershenson DM, Schmeler KM, Malpica A, Fader AN, Frumovitz M. **Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.** *Obstet Gynecol.* 2019 Dec;134(6):1253-1259. doi: 10.1097/AOG.0000000000003579. PMID: 31764736 Clinical Trial.
30. Labrie M, Kendsersky ND, Ma H, Campbell L, Eng J, Chin K, Mills GB. **Proteomics advances for precision therapy in ovarian cancer.** *Expert Rev Proteomics.* 2019 Oct;16(10):841-850. doi: 10.1080/14789450.2019.1666004. Epub 2019 Sep 13. PMID: 31512530 Review.
31. Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. **Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.** *Oncotarget.* 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28. PMID: 31191824
32. LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. **Exploring and comparing adverse events between PARP inhibitors.** *Lancet Oncol.* 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. PMID: 30614472 Review.
33. Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK. **Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.** *Sci Rep.* 2019 Nov 26;9(1):17589. doi: 10.1038/s41598-019-53872-1. PMID: 31772388
34. Li X, Mak VCY, Zhou Y, Wang C, Wong ESY, Sharma R, Lu Y, Cheung ANY, Mills GB, Cheung LWT. **Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.** *Nat Commun.* 2019 Feb 12;10(1):716. doi: 10.1038/s41467-019-08574-7. PMID: 30755611

35. Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM. **BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.** *Cancer Discov.* 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13. PMID: 30425037 Clinical Trial.
36. Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. **GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.** *Mol Cancer Ther.* 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29. PMID: 30926640
37. Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL. **Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).** *JNCI Cancer Spectr.* 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb. PMID: 32337492
38. Mao W, Peters HL, Sutton MN, Orozco AF, Pang L, Yang H, Lu Z, Bast RC Jr. **The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.** *Cancer.* 2019 Apr 15;125(8):1267-1280. doi: 10.1002/cncr.31935. Epub 2019 Jan 8. PMID: 30620384
39. Mao A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K. **Emerging serine-threonine kinase inhibitors for treating ovarian cancer.** *Expert Opin Emerg Drugs.* 2019 Dec;24(4):239-253. doi: 10.1080/14728214.2019.1696773. PMID: 31755325
40. Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM. **Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.** *Gynecol Oncol.* 2019 May;153(2):230-237. doi: 10.1016/j.ygyno.2019.02.003. Epub 2019 Feb 20. PMID: 30797590
41. Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun C, Wang XS, Lu KH, Ramirez PT. **Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.** *Gynecol Oncol.* 2019 Mar;152(3):501-508. doi: 10.1016/j.ygyno.2018.10.044. PMID: 30876495
42. Naumann RW, Coleman RL, Brown J, Moore KN. **Phase III trials in ovarian cancer: The evolving landscape of front line therapy.** *Gynecol Oncol.* 2019 May;153(2):436-444. doi: 10.1016/j.ygyno.2019.02.008. Epub 2019 Feb 12. PMID: 30765149 Review.
43. Nebgen DR, Lu KH, Bast RC Jr. **Novel Approaches to Ovarian Cancer Screening.** *Curr Oncol Rep.* 2019 Jul 26;21(8):75. doi: 10.1007/s11912-019-0816-0. PMID: 31346778 Review.
44. Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. **Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.** *Cancer Lett.* 2019 Feb 1;442:464-474. doi: 10.1016/j.canlet.2018.11.023. Epub 2018 Nov 29. PMID: 30503552
45. Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. **Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.** *Gynecol Oncol.* 2019 Sep;154(3):524-530. doi: 10.1016/j.ygyno.2019.07.004. Epub 2019 Jul 25. PMID: 31353053 Clinical Trial.
46. Rayes N, Bowen DJ, Coffin T, Nebgen D, Peterson C, Munsell MF, Gavin K, Lechner R, Crase J, Polinsky D, Romero I, Blank SV, Levine DA, Norquist BM, Swisher EM, Lu KH. **MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.** *BMC Cancer.* 2019 Jul 2;19(1):648. doi: 10.1186/s12885-019-5868-x. PMID: 31266460

47. Rodriguez-Aguayo C, Bayraktar E, Ivan C, Aslan B, Mai J, He G, Mangala LS, Jiang D, Nagaraja AS, Ozpolat B, Chavez-Reyes A, Ferrari M, Mitra R, Siddik ZH, Shen H, Yang X, Sood AK, Lopez-Berestein G. **PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.** *EBioMedicine*. 2019 Feb;40:290-304. doi: 10.1016/j.ebiom.2018.11.045. Epub 2019 Jan 14. PMID: 30655206
48. Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW. **Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.** *Genome Biol*. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3. PMID: 31771620
49. Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C. **Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.** *Cancer Immunol Immunother*. 2019 Nov;68(11):1747-1757. doi: 10.1007/s00262-019-02402-z. Epub 2019 Oct 10. PMID: 31602489
50. Sans M, Zhang J, Lin JQ, Feider CL, Giese N, Breen MT, Sebastian K, Liu J, Sood AK, Eberlin LS. **Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer.** *Clin Chem*. 2019 May;65(5):674-683. doi: 10.1373/clinchem.2018.299289. Epub 2019 Feb 15. PMID: 30770374
51. Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, Difeo A, Scacheri PC, Adli M. **Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.** *Cancer Res*. 2019 Sep 15;79(18):4599-4611. doi: 10.1158/0008-5472.CAN-19-0215. Epub 2019 Jul 29. PMID: 31358529
52. Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. **PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.** *Cancer Res*. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27. PMID: 30482774
53. Shen W, Niu N, Lawson B, Qi L, Zhang J, Li T, Zhang H, Liu J. **GATA6: a new predictor for prognosis in ovarian cancer.** *Hum Pathol*. 2019 Apr;86:163-169. doi: 10.1016/j.humpath.2019.01.001. Epub 2019 Jan 8. PMID: 30633927
54. Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell GL, Conrads T, Sood AK, Orr D, Holmes LM, Gevaert M, Crosswell HE, DesRochers TM. **Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.** *Sci Rep*. 2019 Aug 1;9(1):11153. doi: 10.1038/s41598-019-47578-7. PMID: 31371750
55. Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, Lu KH, Jacobs I, Skates S, Menon U, Bast RC Jr. **Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.** *Cancer Prev Res (Phila)*. 2019 Jun;12(6):391-400. doi: 10.1158/1940-6207.CAPR-18-0377. Epub 2019 Apr 9. PMID: 30967390
56. Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC Jr, Lu KH, Koopmeiners JS. **Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection.** *Cancer Prev Res (Phila)*. 2019 Mar;12(3):171-184. doi: 10.1158/1940-6207.CAPR-18-0221. Epub 2019 Feb 1. PMID: 30709840
57. Srivastava AK, Banerjee A, Cui T, Han C, Cai S, Liu L, Wu D, Cui R, Li Z, Zhang X, Xie G, Selvendiran K, Patnaik S, Karpf AR, Liu J, Cohn DE, Wang QE. **Inhibition of miR-328-3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer.** *Cancer Res*. 2019 May 1;79(9):2314-2326. doi: 10.1158/0008-5472.CAN-18-3668. Epub 2019 Mar 20. PMID: 30894370
58. Suidan RS, He W, Sun CC, Zhao H, Rauh-Hain JA, Fleming ND, Lu KH, Giordano SH, Meyer LA. **Total and out-of-pocket costs of different primary management strategies in ovarian cancer.** *Am J Obstet Gynecol*. 2019 Aug;221(2):136.e1-136.e9. doi: 10.1016/j.ajog.2019.04.005. Epub 2019 Apr 6. PMID: 30965052 *Clinical Trial*.

59. Sutton MN, Huang GY, Liang X, Sharma R, Reger AS, Mao W, Pang L, Rask PJ, Lee K, Gray JP, Hurwitz AM, Palzkill T, Millward SW, Kim C, Lu Z, Bast RC Jr. **DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1**. *Cancers (Basel)*. 2019 Apr 18;11(4):557. doi: 10.3390/cancers11040557. PMID: 31003488
60. Sutton MN, Huang GY, Zhou J, Mao W, Langley R, Lu Z, Bast RC Jr. **Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression**. *Cancers (Basel)*. 2019 Apr 30;11(5):603. doi: 10.3390/cancers11050603. PMID: 31052266
61. Sutton MN, Lu Z, Li YC, Zhou Y, Huang T, Reger AS, Hurwitz AM, Palzkill T, Logsdon C, Liang X, Gray JW, Nan X, Hancock J, Wahl GM, Bast RC Jr. **DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters**. *Cell Rep*. 2019 Dec 10;29(11):3448-3459.e6. doi: 10.1016/j.celrep.2019.11.045. PMID: 31825828
62. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. **Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer**. *J Clin Oncol*. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19. PMID: 31216226 Clinical Trial.
63. Trudel-Fitzgerald C, Poole EM, Sood AK, Okereke OI, Kawachi I, Kubzansky LD, Tworoger SS. **Social Integration, Marital Status, and Ovarian Cancer Risk: A 20-Year Prospective Cohort Study**. *Psychosom Med*. 2019 Nov/Dec;81(9):833-840. doi: 10.1097/PSY.0000000000000747. PMID: 31592935
64. Uccella S, Fagotti A, Zannoni GF, Coleman RL. **Presumed early ovarian cancer with isolated tumor cells in para-aortic sentinel nodes**. *Int J Gynecol Cancer*. 2019 Jan;29(1):216-220. doi: 10.1136/ijgc-2018-000005. PMID: 30640707 No abstract available.
65. Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc. **Joint ENGOT and GOG Foundation requirements for trials with industry partners**. *Int J Gynecol Cancer*. 2019 Sep;29(7):1094-1097. doi: 10.1136/ijgc-2019-000441. Epub 2019 Jul 18. PMID: 31320391 No abstract available.
66. Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK. **Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4**. *Mol Cancer Ther*. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12. PMID: 30420565
67. Wang Z, Sun K, Xiao Y, Feng B, Mikule K, Ma X, Feng N, Vellano CP, Federico L, Marszalek JR, Mills GB, Hanke J, Ramaswamy S, Wang J. **Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models**. *Sci Rep*. 2019 Feb 12;9(1):1853. doi: 10.1038/s41598-019-38534-6. PMID: 30755715
68. Webber K, Carolus E, Mileskin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M. **OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors**. *Gynecol Oncol*. 2019 Oct;155(1):126-134. doi: 10.1016/j.ygyno.2019.08.009. Epub 2019 Aug 13. PMID: 31416612
69. Yang H, Shu Z, Jiang Y, Mao W, Pang L, Redwood A, Jeter-Jones SL, Jennings NB, Ornelas A, Zhou J, Rodriguez-Aguayo C, Bartholomeusz G, Iles LR, Zacharias NM, Millward SW, Lopez-Berestein G, Le XF, Ahmed AA, Piwnicka-Worms H, Sood AK, Bast RC, Lu Z. **6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers**. *Clin Cancer Res*. 2019 Sep 15;25(18):5702-5716. doi: 10.1158/1078-0432.CCR-18-3448. Epub 2019 Aug 7. PMID: 31391192
70. Yang T, Zhou R, Yu S, Yu S, Cui Z, Hu P, Liu J, Qiao Q, Zhang J. **Cytoplasmic SIRT1 inhibits cell migration and invasion by impeding epithelial-mesenchymal transition in ovarian carcinoma**. *Mol*

Cell Biochem. 2019 Sep;459(1-2):157-169. doi: 10.1007/s11010-019-03559-y. Epub 2019 Jul 17. PMID: 31317367

71. Yeung TL, Sheng J, Leung CS, Li F, Kim J, Ho SY, Matzuk MM, Lu KH, Wong STC, Mok SC. **Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.** J Natl Cancer Inst. 2019 Mar 1;111(3):272-282. doi: 10.1093/jnci/djy097. PMID: 29860390
72. Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK. **Mechanisms of nuclear content loading to exosomes.** Sci Adv. 2019 Nov 20;5(11):eaax8849. doi: 10.1126/sciadv.aax8849. eCollection 2019 Nov. PMID: 31799396